Singh, Deependra VikramAgarwal, AniruddhaGoyal, AnubhavShroff, DaraiusSingh, JatinderKumar, PradeepReddy, Raja RamiVenkatesh, RameshNarnaware, ShilpiJoshi, ShrinivasDelhi Retina Forum Study GroupSingh, Deependra VNarula, RiteshJoshi, AishwaryaAgarwal, AniruddhaGoyal, AnubhavGupta, CharuShroff, DaraiusAnantharaman, GiridharSingh, JatinderKumar, PradeepBawankule, PrashantReddy, Raja RamiJain, RajivVenkatesh, RameshTiwari, RuchirSugumar, ShaliniGupta, Shashank RaiNarnaware, ShilpiJoshi, ShrinivasChoudhary, Somendra P2025-05-092025-05-092024-12Singh Deependra Vikram, Agarwal Aniruddha, Goyal Anubhav, Shroff Daraius, Singh Jatinder, Kumar Pradeep, Reddy Raja Rami, Venkatesh Ramesh, Narnaware Shilpi, Joshi Shrinivas, Delhi Retina Forum Study Group, Singh Deependra V, Narula Ritesh, Joshi Aishwarya, Agarwal Aniruddha, Goyal Anubhav, Gupta Charu, Shroff Daraius, Anantharaman Giridhar, Singh Jatinder, Kumar Pradeep, Bawankule Prashant, Reddy Raja Rami, Jain Rajiv, Venkatesh Ramesh, Tiwari Ruchir, Sugumar Shalini, Gupta Shashank Rai, Narnaware Shilpi, Joshi Shrinivas, Choudhary Somendra P. Initial experience with brolucizumab for neovascular age-related macular degeneration (nAMD) in India – Multicentric, real-world study. Indian Journal of Ophthalmology. 2024 Dec; 72(12): 1786-17940301-47381998-3689https://imsear.searo.who.int/handle/123456789/245110Purpose: To evaluate the anatomic and visual outcomes and safety profile of initial Indian eyes with neovascular age?related macular degeneration (nAMD) treated with intravitreal injection (IVI) of brolucizumab. Methods: This retrospective multicentric, real?world study enrolled consecutive eyes with nAMD that were treated with IVI brolucizumab after it was launched in India in October 2020. Data collected for each eye included best?corrected visual acuity (BCVA), central subfield thickness (CSFT), subretinal fluid (SRF), and intraretinal fluid (IRF) status at 6, 12, and 24 months follow?up. Also recorded were the lens status, treatment protocol, number of injections received before enrollment (in switch?over cases), total number of injections, and adverse effects noticed during the study period. Primary outcomes were change in BCVA, CSFT at follow?up visits, and incidence of intraocular inflammation (IOI). Secondary outcomes were profile of macular neovascularization, treatment protocols, mean number of injections, and maximum injection?free interval observed in eyes treated by pro?re?nata(PRN) protocol. Results: In total, 331 eyes received a mean of 3.55± 1.83 injections. Most frequent treatment protocol was PRN(53%). BCVA data was available for 100%, 96%, and 74% eyes at 6, 12, and 24months follow?up. BCVA and CSFT improved significantly (P < 0.001) at all follow?ups. Two hundred and seventy?six(83.38%) out of 331 eyes received more than one injection; out of these, 241 (87.3%) eyes that were treated by PRN protocol could achieve mean “maximum injection?free interval” of 19.43± 8.82 weeks. IOI and retinal vasculitis were reported in 2.11%(7/331) and 0.60% (2/331) eyes, respectively. None of the eyes with IOI or vasculitis lost any vision at the final follow?up.Conclusion: This study demonstrated favorable visual and anatomic outcomes and safety profile for eyes with nAMD treated by IVI brolucizumab. Mean maximum injection?free interval in eyes treated with PRN was 19weeks.Brolucizumabneovascular AMDvascular endothelial growth factorJournal ArticleIndiaRetina Department, Vitreo-retinal Services, Eye-Q Superspecialty Eye Hospitals Gurugram, Haryana, IndiaRetina Department, The Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates (UAE); Retina Department, The Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates (UAE), Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA; Department of Ophthalmology, Maastricht University Medical Center, Maastricht, The NetherlandsRetina Department, Giridhar Eye Institute, Ernakulum, Kerala, IndiaRetina Department, Shroff Eye Center, Kailash Colony, New Delhi, IndiaRetina Department, Vitreo-retinal Services, The Eye Foundation, Coimbatore, Tamil Nadu, IndiaDepartment of Ophthalmology, Army Hospital Research Referral, Delhi Cantt, New Delhi, IndiaRetina Department, Neo-Retina Eyecare Institute, Chapel Road Nampally Hyderabad, Telangana, IndiaRetina Department, Narayana Nethralaya Eye Hospital, Bengaluru, Karnataka, IndiaVitreoretina Department, Sarakshi Netralaya, Nagpur, Maharashtra, IndiaRetina Department, M M Joshi Eye Hospital, Gokul Road, Sadashiv Nagar Hubli, Karnataka, IndiaRetina Department, Vitreo-retinal Services, Eye-Q Superspecialty Eye Hospitals Gurugram, Haryana, IndiaRetina Department, Vitreo-retinal Services, Eye-Q Superspecialty Eye Hospitals Gurugram, Haryana, IndiaRetina Department, Smt Kanuri Santhamma Centre for Vitreo Retinal Diseases, L V Prasad Eye Institute Banjara Hills, Hyderabad, Telangana, IndiaRetina Department, Narayana Nethralaya Eye Hospital, Bengaluru, Karnataka, IndiaRetina Department, The Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates (UAE); Retina Department, The Eye Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates (UAE), Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA; Department of Ophthalmology, Maastricht University Medical Center, Maastricht, The NetherlandsRetina Department, Giridhar Eye Institute, Ernakulum, Kerala, IndiaRetina Department, Shroff Eye Center, Kailash Colony, New Delhi, IndiaRetina Department, Shroff Eye Center, Kailash Colony, New Delhi, IndiaRetina Department, Giridhar Eye Institute, Ernakulum, Kerala, IndiaRetina Department, Vitreo-retinal Services, The Eye Foundation, Coimbatore, Tamil Nadu, IndiaDepartment of Ophthalmology, Army Hospital Research Referral, Delhi Cantt, New Delhi, IndiaVitreoretina Department, Sarakshi Netralaya, Nagpur, Maharashtra, IndiaRetina Department, Neo-Retina Eyecare Institute, Chapel Road Nampally Hyderabad, Telangana, IndiaRetina Department, Save Sight Centre, Adarsh Nagar, Delhi, IndiaRetina Department, Narayana Nethralaya Eye Hospital, Bengaluru, Karnataka, IndiaRetina Department, Vitreo-retina Services, Tewari Eye Centre, Uttar Pradesh, IndiaRetina Department, Neo-Retina Eyecare Institute, Chapel Road Nampally Hyderabad, Telangana, IndiaRetina Department, Delhi Eye Care 4/17, Balraj Khanna Marg East Patel Nagar, New Delhi, IndiaVitreoretina Department, Sarakshi Netralaya, Nagpur, Maharashtra, IndiaRetina Department, M M Joshi Eye Hospital, Gokul Road, Sadashiv Nagar Hubli, Karnataka, IndiaRetina Department, Complete Eye Care Centre Manish Chamber, Mayur Vihar Phase-2, Delhi, India